Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers

被引:624
作者
Mutter, GL
Lin, MC
Fitzgerald, JT
Kum, JB
Baak, JPA
Lees, JA
Weng, LP
Eng, C
机构
[1] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[2] Natl Taiwan Univ Hosp, Dept Pathol, Taipei 100, Taiwan
[3] Ohio State Univ, Ctr Comprehens Canc, Clin Canc Genet Program, Columbus, OH 43210 USA
[4] Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA
[5] Dana Farber Canc Inst, Charles A Dana Human Canc Genet Unit, Boston, MA 02115 USA
[6] Medisch Centrum Alkmaar, Dept Pathol, Alkmaar, Netherlands
[7] Free Univ Amsterdam Hosp, Amsterdam, Netherlands
[8] MIT, Cambridge, MA 02139 USA
[9] Univ Cambridge, Canc Res Campaign Human Canc Genet Res Grp, Cambridge CB2 1TN, England
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2000年 / 92卷 / 11期
关键词
D O I
10.1093/jnci/92.11.924
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: PTEN tumor suppressor gene mutations are the most frequent genetic lesions in endometrial adenocarcinomas of the endometrioid subtype. Testing the hypothesis that altered PTEN function precedes the appearance of endometrial adenocarcinoma has been difficult, however, partly because of uncertainties in precancer diagnosis. Methods: Two series of endometrial cancer and precancer (endometrial intraepithelial neoplasia, as diagnosed by computerized morphometric analysis) tissue samples were studied, one for PTEN mutations by the use of denaturing gradient gel electrophoresis and another for PTEN protein expression by immunohistochemistry. Endometria altered by high estrogen levels that are unopposed by progestins-conditions known to increase cancer risk-were also studied by immunohistochemistry, Fisher's exact test was used for statistical analysis. Results: The PTEN mutation rate was 83% (25 of 30) in endometrioid endometrial adenocarcinomas and 55% (16 of 29) in precancers, and the difference in number of mutations was statistically significant (two-sided P = .025), No normal endometria showed PTEN mutations, Although most precancers and cancers had a mutation in only one PTEN allele, endometrioid endometrial adenocarcinomas showed complete loss of PTEN protein expression in 61% (20 of 33) of cases, and 97% (32 of 33) showed at least some diminution in expression. Cancers and most precancers exhibited contiguous groups of PTEN-negative glands, while endometria altered by unopposed estrogens showed isolated PTEN-negative glands. Conclusions: Loss of PTEN function by mutational or other mechanisms is an early event in endometrial tumorigenesis that may occur in response to known endocrine risk factors and offers an informative immunohistochemical biomarker for premalignant disease, Individual PTEN-negative glands in estrogen-exposed endometria are the earliest recognizable stage of endometrial carcinogenesis, Proliferation into dense clusters that form discrete premalignant lesions follows.
引用
收藏
页码:924 / 931
页数:8
相关论文
共 39 条
  • [1] Baak JP, 1991, Manual of quantitative pathology in cancer diagnosis and prognosis
  • [2] ARCHITECTURAL AND NUCLEAR MORPHOMETRICAL FEATURES TOGETHER ARE MORE IMPORTANT PROGNOSTICATORS IN ENDOMETRIAL HYPERPLASIAS THAN NUCLEAR MORPHOMETRICAL FEATURES ALONE
    BAAK, JPA
    NAUTA, JJP
    WISSEBREKELMANS, ECM
    BEZEMER, PD
    [J]. JOURNAL OF PATHOLOGY, 1988, 154 (04) : 335 - 341
  • [3] A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens
    Bergeron, C
    Nogales, FF
    Masseroli, M
    Abeler, V
    Duvillard, P
    Müller-Holzner, E
    Pickartz, H
    Wells, M
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1999, 23 (09) : 1102 - 1108
  • [4] PREDICTING THE OUTCOME OF ENDOMETRIAL HYPERPLASIA BY QUANTITATIVE-ANALYSIS OF NUCLEAR FEATURES USING A LINEAR DISCRIMINANT FUNCTION
    COLGAN, TJ
    NORRIS, HJ
    FOSTER, W
    KURMAN, RJ
    FOX, CH
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1983, 1 (04) : 347 - 352
  • [5] A highly conserved processed PTEN pseudogene is located on chromosome band 9p21
    Dahia, PLM
    FitzGerald, MG
    Zhang, X
    Marsh, DJ
    Zheng, ZM
    Pietsch, T
    von Deimling, A
    Haluska, FG
    Haber, DA
    Eng, C
    [J]. ONCOGENE, 1998, 16 (18) : 2403 - 2406
  • [6] PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies
    Dahia, PLM
    Aguiar, RCT
    Alberta, J
    Kum, JB
    Caron, S
    Sill, H
    Marsh, DJ
    Ritz, J
    Freedman, A
    Stiles, C
    Eng, C
    [J]. HUMAN MOLECULAR GENETICS, 1999, 8 (02) : 185 - 193
  • [7] Use of computerized morphometric analyses of endometrial hyperplasias in the prediction of coexistent cancer
    Dunton, CJ
    Baak, JPA
    Palazzo, JP
    vanDiest, PJ
    McHugh, M
    Widra, EA
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1996, 174 (05) : 1518 - 1521
  • [8] Eng C, 1998, INT J ONCOL, V12, P701
  • [9] Genetic testing: The problems and the promise
    Eng, C
    Vijg, J
    [J]. NATURE BIOTECHNOLOGY, 1997, 15 (05) : 422 - 426
  • [10] GRAY LA, 1977, OBSTET GYNECOL, V49, P385